CAPSULES AND CAPSULE COATINGS FOR GASTRIC RESIDENCE DOSAGE FORMS
Disclosed herein are coatings for an encapsulated gastric residence system. The coating includes 50-95 wt. % reverse-enteric polymer; 3-25 wt. % anti-tacking agent; and 1-20 wt. % plasticizer.
1 . A coating for an encapsulated gastric residence system, the coating comprising:
50-95 wt. % reverse-enteric polymer;
3-25 wt. % anti-tacking agent; and
1-20 wt. % plasticizer.
2 . The coating of claim 1 , wherein the coating is on a surface of a capsule, forming a coated capsule.
3 . The coating of claim 2 , wherein the coated capsule encapsulates a gastric residence system to form a gastric residence dosage form, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration.
4 . The coating of claim 1 , comprising 5 to 35 wt. % at least one of a polyvinylpryrrolidone, a vinylpyrrolidone-vinyl acetate copolymer, a polyethylene glycol, mannitol, or hydroxypropyl methylcellulose.
5 . The coating of claim 1 , wherein the reverse-enteric polymer comprises a polymethacrylate-based polymer, the anti-tacking agent comprises at least one of talc or magnesium stearate, and the plasticizer comprises a phthalate, a phosphate, a citrate, a tartrate, an adipate, a sebacate, a sulfonamide, a succinate, a glycolate, a glycerolate, a benzoate, a myristate, a polyethylene glycol, a halogenated phenyl, or a poloxamer.
6 . The coating of claim 1 , wherein the coating is soluble in at least one of an aqueous solution or an organic solution.
7 . The coating of claim 3 , wherein the gastric residence dosage form allows the gastric residence system to assume the open configuration in a first amount of time when exposed to an aqueous pH 7.0 environment, and the first amount of time is greater than a second amount of time for the gastric residence dosage form to allow the gastric residence system to assume an open configuration when the gastric residence dosage form is exposed to an aqueous pH 3.0 environment.
8 . A gastric residence dosage form comprising the coating of claim 1 , wherein the gastric residence dosage form is used to treat a human.